



## HIV AND AIDS

### *CU characterization:*

**CU name:**

HIV and AIDS

**Scientific area acronym:**

BM

**Duration:**

Quarterly

**Working hours:**

84

**Contact hours:**

22

**ECTS:**

2

**Observations:**

N/A

### *Teacher in charge and respective teaching load in the CU:*

João Piedade – 18 hours

### *Other teachers and respective teaching load in the CU:*

Ricardo Parreira – 7.5 hours

### *Intended learning outcomes (knowledge, skills and competences to be developed by the students):*

After this unit, students should be able:

1. To know the main characteristics of the *Retroviridae* family, including the specificities of human retroviruses and related pathologies.
2. To describe the human immunodeficiency virus (HIV) and to understand the different steps of its replication cycle.
3. To interpret the phylogenetic relationships among Primate immunodeficiency viruses and to infer about the biological origin of HIV-1/HIV-2.



## HIV AND AIDS

*Intended learning outcomes (knowledge, skills and competences to be developed by the students): (continuation)*

4. To recognize the biological mechanisms generating genetic variability in retroviruses and their consequences.
5. To describe the natural history of HIV infection, relating to the host immune response and understanding the immunopathogenic mechanisms of infection.
6. To interpret different algorithms for diagnostics/laboratory monitoring of HIV infection and to select the tests to be carried out according to different objectives.
7. To select and to apply screening enzyme immunoassays (ELISA and rapid tests) and confirmatory tests (Western blot) in the diagnostics of HIV-1/-2 infection.

### *Syllabus:*

- I. Family *Retroviridae*. Human retroviruses and associated pathologies. Virion morphology and genome organization. Replication cycle. The human immunodeficiency virus (HIV).
- II. Biological origin and phylogenetic relationships of HIV-1/HIV-2 to Primate lentiviruses. Zoonotic-like transmission. Evolutionary trends of the pandemics.
- III. Genetic variation and molecular epidemiology. Biological mechanisms of variability. Quasispecies. Types, groups, subtypes and sub-subtypes of HIV. Mosaic viruses, unique recombinant forms and circulating recombinant forms. Worldwide geographical distribution of the different types, groups and viral subtypes: causes and effects. Molecular epidemiology of HIV infection in Portugal.
- IV. Natural history of infection. Host immune response. Acute infection, chronic infection and AIDS. Opportunistic infections.
- V. Genetic diversity and resistance to antiretrovirals (ARVs). Concept of “virological failure”. Factors involved in the emergence of resistance. Drug targets and drug classes. Infection monitoring: ARV susceptibility testing. Genotypic and phenotypic tests: fundamentals, interpretation and main advantages and limitations.
- VI. Diagnostics in HIV infection. Immunoenzymatic and immunochromatographic tests (ELISA and rapid tests) and confirmation tests (Western-blot and nucleic acid tests). WHO and CDC algorithms. Special cases: direct detection of the virus (PCR, RT-PCR, p24 antigenaemia). In vitro viral isolation.



## HIV AND AIDS

### *Teaching methodologies (including assessment):*

The total contact hours (20 hrs.) will be distributed by four lectures (12 hrs.), theoretical and practical sessions (2 hrs.), a class of laboratory practice (4 hrs.) and a tutorial (2 hrs.). A total workload of about 60 hrs. is expected for the student. The final assessment will be carried out through a final written exam (2 hrs.), consisting of different type of questions, e.g. multiple choice, true/false, space filling, subtitling, essay questions (100% of the final grade).

### *References for consultation / mandatory existence:*

- Alexander TS (2016). Human immunodeficiency virus diagnostic testing: 30 years of evolution. *Clin. Vaccine Immunol.*, 23:249-53.
- Brun-Vézinet F, Charpentier C (2013). Update on the human immunodeficiency virus. *Méd. Mal. Infect.*, 43:177-84.
- Cortez KJ, Maldarelli F (2011). Clinical management of HIV drug resistance. *Viruses*, 3: 347-78.
- Hemelaar J (2012). The origin and diversity of the HIV-1 pandemic. *Trends Mol. Med.*, 18:182-92.
- Hurt CB, et al. (2017). Selecting an HIV test: a narrative review for clinicians and researchers. *Sex. Transm. Dis.*, 44:739-46.
- Kuritzkes DR, Walker BD (2007). HIV-1 pathogenesis, clinical manifestations and treatment. in "Fields Virology", pp. 2187-2214. Knipe DM et al. (eds.), Wolters Kluwer Health e Lippincott Williams & Wilkins, Philadelphia, EUA, 5ª Ed.
- Okulicz JF (2012). Elite controllers and long-term nonprogressors: models for HIV vaccine development? *J. AIDS Clinic. Res.*, 3:139. doi:10.4172/2155-6113.1000139.
- Peeters M, et al. (2013). The origin and molecular epidemiology of HIV. *Expert Rev. Anti Infect. Ther.*, 11:885-96.
- Pépin J (2011). The origins of AIDS. Cambridge University Press, Cambridge, Reino Unido.
- Sharp PM, Hahn BH (2011). Origins of HIV and the AIDS pandemic. *Cold Spring Harb. Perspect. Med.*, 1:a006841.
- Sierra S, et al. (2005). Basics of the virology of HIV-1 and its replication. *J. Clin. Virol.*, 34:233-44.
- Tebit DM, Arts EJ (2011). Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. *Lancet Infect. Dis.*, 11:45-56.